Navigation Links
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Date:10/1/2007

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual

Acuity

UNION CITY, Calif., Oct. 1 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced positive interim data from a Phase 1 study of its lead product candidate in patients with chronic, clinically significant diabetic macular edema (DME). Results from this prospective study of 50 patients demonstrated that MacuSight's proprietary formulation of sirolimus (rapamycin) was safe and well-tolerated in all doses tested with two different routes of administration. Additionally investigators noted improvements in visual acuity and foveal thickness reductions for up to 180 days following a single administration of sirolimus. These findings were presented at the 40th Annual Meeting of The Retina Society by Mark Blumenkranz, M.D., chairman of MacuSight's scientific advisory board and professor and chairman of the department of ophthalmology, Stanford University School of Medicine.

As part of the design of this randomized, open-label study, investigators evaluated the safety, tolerability and biological activity of sirolimus when delivered by either subconjunctival or intravitreal injection. Intravitreal injections (into the central cavity of the eye), while the standard route of administration for current therapies, are uncomfortable for many patients and are accompanied by the risk of serious infection in a small percentage of patients. In contrast, subconjunctival injections (just under the outer layer over the white of the eye) are designed to offer physicians and patients a less invasive and more convenient procedure. MacuSight's DME trial included ten treatment arms with patients receiving one of five doses of sirolimus via either a single subconjunctival injection or a single intravitreal injection. Preclinical studies suggested that a single admi
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that it will release its fiscal 2010 ... the market close. The Company will host a conference ... (Eastern Time) to discuss the results. ,, ... by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also access ...
(Date:12/15/2009)... Robbins & Myers, Inc. (NYSE: ... for its fiscal 2010 first quarter ending November 30, ... 2010. A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive ... Financial Officer, will be discussing the Company,s performance and ...
(Date:12/15/2009)... U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ... no, and 1 abstention that AstraZeneca has established sufficient ... use of CRESTOR® (rosuvastatin calcium) in individuals meeting the ... to 50 years, women greater than or equal to ... hsCRP greater than or equal to 2.0 mg/L; Triglycerides ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 1Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 2Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 3Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 1Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 2Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 3Lots of Schoolkids Squint to See Chalkboard 53528 1
(Date:12/15/2009)... NAPA, Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences ... healthy aging, today announced that shareholders had approved all three resolutions that the Company had ... were as follows: , , Description of ... Votes ... For ...
(Date:12/15/2009)... Lady of Lourdes Health Care Services Inc., the parent ... pay the United States $7.95 million to resolve allegations ... today. The two hospitals are Our Lady of Lourdes ... Center of Burlington County (LMC) in Willingboro, N.J. ... by a whistleblower, Tony Kite, in 2005. The lawsuit ...
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
(Date:12/15/2009)... 15 4R Systems, Inc., a leading ... which help retailers significantly increase profits by optimizing ... today that The Vitamin Shoppe has been utilizing ... store and DC inventory solutions have helped us ... in-stocks over the last two years," said Tony ...
(Date:12/15/2009)... North American application activity for individually underwritten life ... the MIB Life Index(SM) . Solid ... three months have lifted year-to-date (YTD) figures from ... at November,s close, -0.1%. "It is clear ... available from life insurance," says Stacy Gill, MIB ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3
... 8 Sector 10, Inc. (OTC,Bulletin Board: SECT; Frankfurt: ... milestone schedule to start this month with Syptec Internet,Services ... The,deployment is being largely based on private digital alarm ... and is set to scale as large,as 50-53,000 concurrent ...
... almost fivefold, German study finds , , TUESDAY, July 8 ... the more likely it will spread or reoccur, according ... research in the August edition of The Lancet ... tumor thickness were almost five times more likely to ...
... one of the major challenges of the 21st century ... health care systems. Recently, common pathways of the two ... dementia have been suggested. Today there is tremendous interest ... step in the disease cascade or even prevent the ...
... ANGELES, July 8 , WHAT: City of ... 8th,annual La Gota de la Vida campaign to ... treatment institution for cancer and other,life-threatening diseases. The ... National Bone Marrow Registry. This year,s activities,will include ...
... 8 The VHA,Foundation, a foundation focused on ... and the National Business Group on Health (NBGH), ... employers,devoted exclusively to finding innovative solutions to health ... award that recognizes health,systems who are taking a ...
... & Johnson,will host a conference call for financial ... 15, 2008, to review second-quarter results. Dominic,Caruso, Vice ... Vice President, Investor Relations, will host the call., ... the broadcast by,visiting the Company,s website at ...
Other Medicine News:Health News:Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars 2Health News:Paul Rodriguez, Voces Del Rancho and More to Be Honored at the 8th Annual Angels of Hope Awards, July 12 2Health News:Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership 2Health News:Two National Health Organizations to Recognize the Nation's Best Health Systems for Patient Safety Leadership 3
... The Bledsoe Tenderfoot™ Boot features a ... Density technology used in our Conformer boots. ... pre-ulcerative foot conditions in sensate patients, plantar ... or callouses, or any other foot condition ...
... is designed as a flexible and attractive alternative ... mid-foot area and also for second and third ... than the Bledsoe Hi-Top Boot but offers similar ... designed for range of motion from 20 degrees ...
... Diabetic Boot features a fully enclosed thick, ... unique auto-molding innersole which embeds into a ... aluminum shelled walking boot. This unique Automold™ ... distribute body weight across the entire bottom ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: